Industry Roundup: Restoring Access Legislation, Adulterated Ayurvedics, UK Claims Enforcement
This article was originally published in The Tan Sheet
Executive Summary
Mylan, Perrigo more candid in hostile takeover comments; House committee clears Restoring Access bill; UK enforces on supplement ad claims.
You may also be interested in...
Unfettered OTC Purchasing With Pre-Tax Savings Tops CHPA Goals In 2015
CHPA is optimistic 2015 is the year “common sense” will restore OTC eligibility for health spending accounts. Speaking on the group’s priorities, President and CEO Scott Melville said CHPA will work to improve the OTC monograph system and to curb cough medicine abuse.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.